7. Accuray
R&D spending: $57,251,000
Percentage of revenues: 14.1%
2018 overall revenue ranking: 85

[Image from Accuray]
The CyberKnife is used for stereotactic radiosurgery and stereotactic body radiation therapy and includes dynamic tracking and motion compensation. The system, according to Accuray, enables high precise, non-surgical treatment for tumors and lesions anywhere within the body, including the prostate, lung, brain, spine, liver, pancreas and kidney. The system also offers automatic, real-time tumor tracking and motion management to give more precise treatment of a variety of cancers, reducing the therapy’s impact on quality of life.